Table 2.
Molecular aberrations in advanced gynecologic malignancies
| Aberrations | n (%) |
|---|---|
| TP53 | 42 (20.10) |
| KRAS | 14 (6.70) |
| PIK3CA | 11 (5.26) |
| PIK3R1 | 9 (4.31) |
| ATR | 8 (3.83) |
| PTEN | 8 (3.83) |
| BRCA1 | 6 (2.87) |
| NF1 | 4 (1.91) |
| NOTCH1 | 4 (1.91) |
| POLE | 4 (1.91) |
| APC | 3 (1.44) |
| ARID1A | 3 (1.44) |
| ATM | 3 (1.44) |
| CDH1 | 3 (1.44) |
| FBXW7 | 3 (1.44) |
| MAP2K1 | 3 (1.44) |
| PTCH1 | 3 (1.44) |
| RB1 | 3 (1.44) |
| TSC1 | 3 (1.44) |
| TSC2 | 3 (1.44) |
| BRAF | 2 (0.96) |
| CDK12 | 2 (0.96) |
| ERBB3 | 2 (0.96) |
| FANCA | 2 (0.96) |
| FANCI | 2 (0.96) |
| FGFR1 | 2 (0.96) |
| KIT | 2 (0.96) |
| MET | 2 (0.96) |
| MLH1 | 2 (0.96) |
| MSH2 | 2 (0.96) |
| MYC | 2 (0.96) |
| NBN | 2 (0.96) |
| NOTCH2 | 2 (0.96) |
| NOTCH3 | 2 (0.96) |
| NTRK2 | 2 (0.96) |
| PMS2 | 2 (0.96) |
| RAD50 | 2 (0.96) |
| RAD51C | 2 (0.96) |
| SETD2 | 2 (0.96) |
| AKT1 | 1 (0.48) |
| ATRX | 1 (0.48) |
| BRCA2 | 1 (0.48) |
| CCND1 | 1 (0.48) |
| CCND2 | 1 (0.48) |
| CCND3 | 1 (0.48) |
| CDKN2A | 1 (0.48) |
| CHEK1 | 1 (0.48) |
| CHEK2 | 1 (0.48) |
| DDR2 | 1 (0.48) |
| FGFR2 | 1 (0.48) |
| FGFR4 | 1 (0.48) |
| IDH1 | 1 (0.48) |
| MAPK1 | 1 (0.48) |
| MED12 | 1 (0.48) |
| MSH6 | 1 (0.48) |
| MTOR | 1 (0.48) |
| NF2 | 1 (0.48) |
| NTRK1 | 1 (0.48) |
| PALB2 | 1 (0.48) |
| PDGFRA | 1 (0.48) |
| PPP2R1A | 1 (0.48) |
| PTPN11 | 1 (0.48) |
| RET | 1 (0.48) |
| RNF43 | 1 (0.48) |
| SLX4 | 1 (0.48) |
| SMAD4 | 1 (0.48) |
| SMARCA4 | 1 (0.48) |
| SMARCB1 | 1 (0.48) |
| STK11 | 1 (0.48) |
| TERT | 1 (0.48) |
| Total | 209 (100) |